Comparative Pharmacology
Head-to-head clinical analysis: CYCLACILLIN versus NITROFURANTOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLACILLIN versus NITROFURANTOIN.
CYCLACILLIN vs NITROFURANTOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyclacillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
Nitrofurantoin is reduced by bacterial flavoproteins to reactive intermediates that inactivate or inhibit bacterial ribosomal proteins, DNA, RNA, and metabolic enzymes, leading to bacterial cell death.
250-500 mg orally every 6 hours.
100 mg orally twice daily for 5-7 days (uncomplicated UTI); 50-100 mg orally four times daily for 7 days (symptomatic uncomplicated UTI). Extended-release: 100 mg orally twice daily for 7 days.
None Documented
None Documented
0.5–1 hour in adults with normal renal function; prolonged to 10–15 hours in anuria.
Clinical Note
moderateNitrofurantoin + Norfloxacin
"The therapeutic efficacy of Norfloxacin can be decreased when used in combination with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateNitrofurantoin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Nitrofurantoin."
Clinical Note
moderateCyclacillin + Probenecid
Normal renal function: 20-60 minutes; impaired function: prolonged up to 1-2 hours, clinically significant due to urinary concentration requirement
Primarily renal (90%) as unchanged drug via glomerular filtration and tubular secretion; negligible biliary/fecal elimination (<5%).
Renal: ~40% unchanged via glomerular filtration and tubular secretion, biliary/fecal: <1%
Category C
Category D/X
Antibiotic
Antibiotic
"The serum concentration of Probenecid can be increased when it is combined with Cyclacillin."